Bristol-Myers Squibb Co. said the pivotal study of lisocabtagene maraleucel (liso-cel) an investigational CD19-directed CAR T-cell therapy with a defined composition of purified CD8+ and CD4+ CAR T cells in relapsed/refractory large B-cell lymphomas (TRANSCEND NHL 001) met its primary and secondary endpoints while demonstrating durable responses.
Phase II KarMMa study of ide-cel in relapsed, refractory multiple myeloma meets ORR primary endpoint
Results from the KarMMa study, a pivotal, open-label, single arm, multicenter, phase II study of idecabtagene vicleucel met its primary endpoint of overall response rate in the treatment of relapsed and refractory multiple myeloma.
Seattle Genetics Inc. announced positive pivotal data from the HER2CLIMB trial evaluating tucatinib in patients with HER2-positive metastatic breast cancer.
The presence of circulating tumor DNA in early-stage triple-negative breast cancer helped predict the risk of recurrence in women who had undergone surgery after neoadjuvant chemotherapy, a study found.
The phase III E1912 clinical study showed superior progression-free survival and overall survival in patients with chronic lymphocytic leukemia new to treatment.
TOURMALINE-AL1 trial, a phase III, randomized clinical trial evaluating the effect of Ninlaro (ixazomib) in combination with dexamethasone, did not meet the first of the two primary endpoints of significant improvement in overall hematologic response in patients with relapsed or refractory systemic light-chain amyloidosis.
MacroGenics Inc. has presented updated results from the phase III SOPHIA study comparing margetuximab plus chemotherapy versus trastuzumab plus chemotherapy in patients with HER2-positive metastatic breast cancer who have previously been treated with anti-HER2-targeted therapies.
Keytruda (pembrolizumab) showed improvements in overall survival, progression-free survival and objective response rate as monotherapy for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer whose tumors expressed PD-L1 (tumor proportion score [TPS] ≥1%), regardless of KRAS mutational status.
For patients with high-risk myeloid cancers undergoing a donor stem cell transplant, adding the targeted drug venetoclax to a reduced-intensity drug regimen prior to transplant is safe and does not impair the ability of the donor cells to take root in recipients' bodies, a study led by Dana-Farber Cancer Institute researchers suggests.
A study finds more than two-fold differences between counties with the lowest and highest rates of surgery for patients with early stage lung cancer, with socioeconomic and healthcare delivery factors contributing to the gap. The study appears in Chest.